--- title: 'Vice President, Insights & Analytics at Vaxcyte' canonical: 'https://feeny.ai/job/vice-president-insights-analytics-vaxcyte-san-carlos-4xnc9p1wjqa1' type: 'job' last_seen: '2026-11-09' --- # Vice President, Insights & Analytics at Vaxcyte - **Company:** Vaxcyte - **Location:** San Carlos, CA - **Posted:** 2026-11-03 - **Last confirmed live:** 2026-11-09 - **Apply:** https://boards.greenhouse.io/vaxcyte/jobs/5470344008?gh_jid=5470344008 ## Job description Join our Mission to Protect Humankind! Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, which have serious and costly health consequences when left unchecked. Working to eradicate or treat bacterial infections such as invasive pneumococcal disease, Group A Strep, and Shigella is just the beginning. Our path to success is clear and well-defined, and Vaxcyte is set up to go the distance. WHAT we do is every bit as important as HOW we do it! Our work together is guided by four enduring core values: *RETHINK CONVENTION: We bring creative and intellectual diversity to every facet of the work we do in order to innovate and re-innovate the way vaccines are delivered. *AIM HIGH: We embody our collectively audacious goal to courageously make the most complex biologics ever attempted to protect humankind. *LEAD WITH HEART: Everyone leads at Vaxcyte with a kindness-first, inclusive approach to collaboration and vigorous debate that advances our business objectives. *MODEL EXCELLENCE:  The magnitude of our challenge requires our shared commitment to demonstrating integrity, accountability, equality and clarity across communications and decision making. Summary: The Vice President, Insights & Analytics (I&A) is a newly created role responsible for building Vaxcyte’s commercial insights, analytics, and forecasting capabilities, beginning with the U.S. adult launch of VAX-31. This leader will oversee the existing Market Research and Competitive Intelligence team while establishing new commercial analytics capabilities, bringing these functions together into an integrated organization that informs strategic and operational decision-making across the Commercial organization. The VP, I&A will translate market research, customer insights, competitive intelligence, claims data, and commercial performance data into actionable insights that inform strategy, resource allocation, forecasting, and execution. As a trusted advisor to commercial and executive leadership, this role will provide a clear, integrated view of market dynamics, customer needs, competitive developments, and business performance to identify risks and opportunities and support confident, data-driven decisions. This role sits within the Commercial organization and will partner closely with the Commercial Leadership Team, including the Launch Lead and leaders across Marketing, Sales, Market Access, and Digital Enablement, as well as Finance, Medical Affairs, and Scientific Affairs. The role will own the business questions, analytical priorities, interpretation, and communication of insights, while partnering with Digital Enablement, which owns the systems, platforms, and AI-enabled tools that support data access and analytical capabilities at scale. Essential Functions: Insights & Analytics Strategy and Organizational Leadership - Define and execute the I&A strategy, operating model, and phased capability build to support pre-launch, launch, and commercial growth, including organizational design, talent, budget, and external partnerships. - Build and lead a high-performing team spanning market research, competitive intelligence, forecasting, and commercial analytics, establishing I&A as a trusted center of excellence and source of actionable insights across the organization. - Establish data acquisition, governance, and utilization priorities in partnership with Digital Enablement to support integrated, reliable, and timely decision-making. Market Insights, Competitive Intelligence, and Forecasting - Lead market research and competitive intelligence to deepen understanding of healthcare professionals, patients, payers, and the evolving competitive landscape, translating findings into implications for positioning, segmentation, targeting, and go-to-market strategy. - Oversee commercial forecasting, ensuring assumptions are informed by qualitative and quantitative evidence and that key risks, opportunities, and market uncertainties are clearly communicated to leadership. Commercial Analytics and Performance Management - Establish the commercial measurement and reporting framework, including performance metrics, dashboards, and executive-level reporting, to monitor launch progress and inform business decisions. - Deliver actionable analyses and recommendations across sales, marketing, and market access, including account targeting, sales and marketing effectiveness, investment optimization, return on investment, and sales force incentive compensation in partnership with Sales and Finance. - Leverage advanced and AI-enabled analytics in partnership with Digital Enablement to improve analytical efficiency, generate timely insights, and support continuous optimization of commercial execution. Cross-Functional Partnership and Executive Advisory - Partner with commercial leaders to align research, forecasting, and analytics priorities with launch milestones and strategic decisions, ensuring insights are available when needed. - Collaborate with Market Access, Medical Affairs, Scientific Affairs, and other cross-functional partners to integrate relevant perspectives while maintaining appropriate functional independence and compliance boundaries. - Serve as a trusted advisor to the Chief Commercial Officer and executive leadership, clearly communicating business implications, surfacing emerging risks and opportunities, and informing commercial strategy and expectations. Requirements: - BA/BS degree in a scientific discipline, business, or a quantitative field required. MBA or other advanced degree highly desired. - Minimum of 15+ years of industry-related experience, with 7+ years in insights, analytics, forecasting, or market research leadership roles within pharmaceutical, biotech, or vaccine organizations, including direct exposure to vaccine product launch. - Demonstrated experience building an Insights & Analytics function from the ground up, or serving as one of the first I&A hires in a pre-launch or early-launch commercial-stage company. - Deep understanding of vaccine commercial data and analytics ecosystem, including: - Syndicated sales and claims data (e.g., IQVIA, Symphony, Komodo) - Primary and secondary market research methodologies (HCP, patient, and payor) - Forecasting methodologies for complex biologics and vaccines - Competitive intelligence frameworks and tools - Commercial analytics and BI platforms (e.g., Tableau, Power BI) - Working familiarity with AI-enabled analytics tools (predictive modeling, automated insight generation) and the judgment to know when human analysis should lead. - Experience launching U.S. vaccines and/or specialty biologics (highly preferred). - Familiarity with GPO, P&T committee, and payor contracting timelines and how they shape forecast assumptions and research sequencing. - Proven ability to translate complex data into a clear, decision-ready narrative for commercial and executive leadership. - Ability to travel 20% of the time for commercial and cross-functional team engagements. - Other combinations of education and/or experience may be considered. Reports to: Chief Commercial Officer Location: US - Philadelphia, PA Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Hybrid (minimum of 3 days per week onsite) Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component. Salary Range: $325,000 - $385,000. Salary ranges for non-California locations may vary. Relocation: This role is not eligible for relocation assistance. ## Equal Opportunity We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status. Recruitment Fraud Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at [vaxcyte.com/careers](https://vaxcyte.com/careers/). ## About Vaxcyte ## Company Overview - **One-liner**: Vaxcyte is a clinical-stage biotechnology company re-engineering how vaccines are made to eliminate bacterial infections, using a cell-free protein synthesis platform to develop high-fidelity, broad-spectrum vaccines. - **Entity Type**: Public (Ticker: PCVX) - **Headquarters**: San Carlos, California, United States - **Founded**: 2013 (as SutroVax; rebranded to Vaxcyte in 2020) - **Founders**: Not publicly available (the company emerged from Sutro Biopharma’s spin-out) ## Core Business - **Primary industry**: Biotechnology / Vaccines (Infectious Disease) - **Target customers**: Global healthcare systems, public health organizations, and ultimately patients (B2B/Institutional); the company develops vaccines for both pediatric and adult populations. - **Mission or purpose**: To protect humankind from the consequences of bacterial infections, eliminating diseases like invasive pneumococcal disease, Group A Strep, and Shigella. ## Products & Services - **VAX-31 (31-valent PCV)**: A broad-spectrum pneumococcal conjugate vaccine candidate in Phase 3 for adults and Phase 2 for infants. Designed to cover over 95% of circulating IPD serotypes in U.S. adults 50+ and ~94% in infants. FDA Breakthrough Therapy designation granted. - **VAX-24 (24-valent PCV)**: A pneumococcal conjugate vaccine candidate in Phase 2 for infants, designed to cover more serotypes than any infant PCV on the market today. - **VAX-A1 (Group A Strep)**: A preclinical conjugate vaccine candidate for Group A Strep, a disease with no currently approved vaccine. Phase 1 first-in-human study (adults) underway in Australia. - **VAX-GI (Shigella)**: A novel preclinical vaccine candidate targeting Shigella, a leading cause of diarrheal disease. - **Platform Technology**: A proprietary cell-free protein synthesis platform that enables site-specific, carrier-sparing conjugation to produce precisely targeted vaccines with enhanced immunogenicity. ## Market Standing - **Valuation/Market Cap**: ~$16.7 billion (as of early July 2026) - **Key Metric**: Total funding raised (private) is not applicable; as a public company, key metrics include cash position (~$2.0 billion as of Q1 2026) and R&D investment. The company is pre-revenue. - **Notable Investors/Partners**: Major institutional investors include Baker Bros. Advisors, Fidelity, and funds managed by BlackRock. Key partnership: exclusive license agreement with Sutro Biopharma for its cell-free protein synthesis platform. - **Growth Signals**: - Up to $1 billion commitment to expanding U.S. manufacturing with a new facility in North Carolina. - VAX-31 Phase 3 program (OPUS-1, OPUS-2, OPUS-3) topline data expected Q4 2026 – H1 2027. - Headcount growth: actively hiring across 100+ roles (Analytical, Commercial, Clinical, Conjugation, Quality, Regulatory). - Recognized as a Great Place to Work and Best Workplace in BioPharma (multiple years). ## Competitive Advantages - **Broadest-spectrum PCV candidates**: VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in the clinic, targeting up to 31 serotypes. - **Differentiated platform**: Cell-free protein synthesis allows for the creation of complex, high-fidelity vaccines that can overcome bacterial defense mechanisms (e.g., capsule-switching) that limit conventional cell-based vaccines. - **Carrier-sparing technology**: Site-specific conjugation enables a higher valency (more serotypes) without compromising immunogenicity or tolerability. - **Manufacturing scale**: Significant investment in U.S.-based production capacity provides a long-term supply chain advantage and aligns with "Investing in America" initiatives. ## Strategic Focus - **Primary**: Advance VAX-31 and VAX-24 through late-stage clinical trials to secure regulatory approval and establish a new standard of care for pneumococcal disease. - **Pipeline expansion**: Advance VAX-A1 (Group A Strep) and VAX-GI (Shigella) candidates through early clinical development. - **Manufacturing**: Scale up internal manufacturing capabilities to support commercial launch and global supply. - **Commercial readiness**: Building a commercial organization (e.g., hiring a VP of U.S. Market Access & Pricing, Senior Director of Product Launch) to prepare for potential VAX-31 launch. ## Why Work Here - **Culture**: Described as a "kindness-first" mindset with a focus on audacious goals, collaboration, and mutual support. Recognized as a *Great Place to Work* and *Best Workplace in BioPharma* (Fortune). - **Work Model**: Hybrid, Remote, and Onsite options available depending on role. San Carlos HQ offers a hybrid schedule. - **Total Rewards**: 100% paid health, dental, and vision insurance; 401k matching; flexible PTO and holidays; paid parental and sick leave; equity awards (stock options & RSUs); Employee Stock Purchase Plan; lifestyle spending account; mental health and wellness resources. - **Growth & Development**: Strong emphasis on learning culture, professional advancement through coaching, and career development programs. - **Mission-driven**: Employees are directly contributing to creating vaccines that protect every child born and every adult at risk from bacterial infections globally. ## Sources 1. [vaxcyte.com](https://vaxcyte.com/) 2. [vaxcyte.com/careers](https://vaxcyte.com/careers/) 3. [vaxcyte.com/job-listings](https://vaxcyte.com/job-listings/) 4. [vaxcyte.com/culture](https://vaxcyte.com/culture/) 5. [vaxcyte.com/pipeline](https://vaxcyte.com/pipeline/) ## Other roles at Vaxcyte - [Scientist II, Analytical Development](https://feeny.ai/job/scientist-ii-analytical-development-vaxcyte-san-carlos-ed0hcxvt9rv5) — San Carlos, CA - [Director, Quality Control Operations](https://feeny.ai/job/director-quality-control-operations-vaxcyte-visp-valais-se41wa0bkvjx) — Visp Valais, Switzerland - [Executive Assistant](https://feeny.ai/job/executive-assistant-vaxcyte-san-carlos-cc1yzaynf06a) — San Carlos, CA - [Associate Director, Business Operations & Digital Enablement](https://feeny.ai/job/associate-director-business-operations-digital-enablement-vaxcyte-san-carlos-1cv5813jhces) — San Carlos, CA - [Associate Director, Business Process Management & Operational Excellence](https://feeny.ai/job/associate-director-business-process-management-operational-excellence-vaxcyte-5p0t7q2tj3a5) — San Carlos, CA - [Manager Accounting , Inventory and Operations](https://feeny.ai/job/manager-accounting-inventory-and-operations-vaxcyte-san-carlos-r66rjpkp6y1a) — San Carlos, CA - [Senior Accountant](https://feeny.ai/job/senior-accountant-vaxcyte-san-carlos-j4sqgfxb13nj) — San Carlos, CA - [Systems Engineer](https://feeny.ai/job/systems-engineer-vaxcyte-san-carlos-zy2wf03ynbzs) — San Carlos, CA - [IT Operations Engineer](https://feeny.ai/job/it-operations-engineer-vaxcyte-san-carlos-y9kstk4b8rz9) — San Carlos, CA - [Manager, Facilities Engineering](https://feeny.ai/job/manager-facilities-engineering-vaxcyte-san-carlos-9z48ebpsa6x8) — San Carlos, CA